Elekta

MEDTECHS DEFLATE FURTHER

13/03/25 -"It has been some time since AlphaValue last bashed MedTechs, its recurring bête noire when it comes to lofty valuations. In fairness the sector has taken care of itself of late. Five years after ..."

PDF page sample
Pages
64
Language
English
Published on
13/03/25
Download
You may also be interested by these reports :
20/08/26
GN reported a weak quarter, impacted by challenging market conditions and subdued consumer sentiment. The decline in the top line was primarily ...
19/08/26
S&N Q2/H1 26 print disappointed: revenue missed consensus, forcing management to cut FY26 revenue growth guidance to 4% from 6%, while Orthopaedics ...
19/08/26
With the release of the 1H results, we have slightly adjusted our expectations. We account for no revenue from pre-approved services in 2026, and ...
18/08/26
Coloplast delivered a mixed Q3 FY26: revenue beat consensus (+1.2%) but EBIT missed (-1%), with the margin declining for a third straight quarter. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO